Serum Adipsin Levels throughout Normal Pregnancy and Preeclampsia

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Poveda, Natalia E ^a   Garcés, María F ^a   Ruiz Linares, Carlos E ^a   Varón, Diana ^a   Valderrama, Sergio ^a   Sanchez, Elizabeth ^a   Castiblanco Cortes, Adriana ^a   Agudelo Zapata, Yessica ^a   Sandoval Alzate, Héctor Fabio ^a   Leal, Luis G ^a   Ángel Müller, Edith ^a   Ruíz Parra, Ariel I ^a   González Clavijo, Angélica M ^a   Diéguez, Carlos ^b,c   Nogueiras, Rubén ^b,c   Caminos, Jorge E ^a  

^a UNIVERSIDAD NACIONAL DE COLOMBIA   (Colombia)

^b UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

^c Instituto de Salud Carlos III   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84957598670     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep20073     Document Type: Article

References (66)

1. White, R. T. et al. Human adipsin is identical to complement factor D and is expressed at high levels in adipose tissue. J. Biol. Chem. 267, 9210-3 (1992).
2. Choy, L. N., Rosen, B. S. & Spiegelman, B. M. Adipsin and an endogenous pathway of complement from adipose cells. J. Biol. Chem. 267, 12736-41 (1992).
3. Cianflone, K., Xia, Z. & Chen, L. Y. Critical review of acylation-stimulating protein physiology in humans and rodents. Biochim. Biophys. Acta 1609, 127-43 (2003).
4. Kalant, D. et al. C5L2 is a functional receptor for acylation-stimulating protein. J. Biol. Chem. 280, 23936-44 (2005).
5. Richani, K. et al. Normal pregnancy is characterized by systemic activation of the complement system. J. Matern. Fetal. Neonatal Med. 17, 239-45 (2005).
6. Tedesco, F. et al. Immunohistochemical detection of terminal complement complex and S protein in normal and pre-eclamptic placentae. Clin. Exp. Immunol. 80, 236-40 (1990).
7. Xu, C. et al. A critical role for murine complement regulator crry in fetomaternal tolerance. Science 287, 498-501 (2000).
8. Holers, V. M., Kinoshita, T. & Molina, H. The evolution of mouse and human complement C3-binding proteins: divergence of form but conservation of function. Immunol. Today 13, 231-6 (1992).
9. Sircar, M., Thadhani, R. & Karumanchi, S. A. Pathogenesis of preeclampsia. Curr. Opin. Nephrol. Hypertens. 24, 131-8 (2015).
10. Rasmussen, L. G., Lykke, J. A. & Staff, A. C. Angiogenic biomarkers in pregnancy: defining maternal and fetal health. Acta Obstet. Gynecol. Scand. 94, 820-32 (2015).
11. Salzer, L., Tenenbaum-Gavish, K. & Hod, M. Metabolic disorder of pregnancy (understanding pathophysiology of diabetes and preeclampsia). Best Pract. Res. Clin. Obstet. Gynaecol. 29, 328-38 (2015).
12. Kaaja, R., Tikkanen, M. J., Viinikka, L. & Ylikorkala, O. Serum lipoproteins, insulin, and urinary prostanoid metabolites in normal and hypertensive pregnant women. Obstet. Gynecol. 85, 353-6 (1995).
13. Buurma, A. et al. Preeclampsia is characterized by placental complement dysregulation. Hypertension 60, 1332-7 (2012).
14. Lokki, A. I. et al. Complement activation and regulation in preeclamptic placenta. Front. Immunol. 5, 312 (2014).
15. Girardi, G., Bulla, R., Salmon, J. E. & Tedesco, F. The complement system in the pathophysiology of pregnancy. Mol. Immunol. 43, 68-77 (2006).
16. Regal, J. F., Gilbert, J. S. & Burwick, R. M. The complement system and adverse pregnancy outcomes. Mol. Immunol. 67, 56-70 (2015).
17. Derzsy, Z., Prohászka, Z., Rigó, J., Föst, G. & Molvarec, A. Activation of the complement system in normal pregnancy and preeclampsia. Mol. Immunol. 47, 1500-6 (2010).
18. Burwick, R. M. & Feinberg, B. B. Eculizumab for the treatment of preeclampsia/HELLP syndrome. Placenta 34, 201-203 (2013).
19. Weir, P. E. Immunofluorescent studies of the uteroplacental arteries in normal pregnancy. Br. J. Obstet. Gynaecol. 88, 301-7 (1981).
20. Girardi, G., Prohászka, Z., Bulla, R., Tedesco, F. & Scherjon, S. Complement activation in animal and human pregnancies as a model for immunological recognition. Mol. Immunol. 48, 1621-30 (2011).
21. Yang, Y. et al. Relationships among acylation stimulating protein, adiponectin and complement C3 in lean vs obese type 2 diabetes. Int. J. Obes. (Lond). 30, 439-46 (2006).
22. Wang, T. et al. Elevation of urinary adipsin in preeclampsia: correlation with urine protein concentration and the potential use for a rapid diagnostic test. Hypertension 64, 846-51 (2014).
23. Maslowska, M., Sniderman, A. D., Germinario, R. & Cianflone, K. ASP stimulates glucose transport in cultured human adipocytes. Int. J. Obes. Relat. Metab. Disord. 21, 261-6 (1997).
24. Yasruel, Z. et al. Effect of acylation stimulating protein on the triacylglycerol synthetic pathway of human adipose tissue. Lipids 26, 495-9 (1991).
25. Bienertová-Vašku, J. et al. The prediction role of indexes of circulating adipokines for common anthropometric and nutritional characteristics of obesity in the obese Central European population. Eat. Behav. 15, 244-51 (2014).
26. Napolitano, A. et al. Concentrations of adipsin in blood and rates of adipsin secretion by adipose tissue in humans with normal, elevated and diminished adipose tissue mass. Int. J. Obes. Relat. Metab. Disord. 18, 213-8 (1994).
27. Schrauwen, P., Hesselink, M. K. C., Jain, M. & Cianflone, K. Acylation-stimulating protein: effect of acute exercise and endurance training. Int. J. Obes. (Lond). 29, 632-8 (2005).
28. Zhang, J., Wright, W., Bernlohr, D. A., Cushman, S. W. & Chen, X. Alterations of the classic pathway of complement in adipose tissue of obesity and insulin resistance. Am. J. Physiol. Endocrinol. Metab. 292, E1433-40 (2007).
29. Lo, J. C. et al. Adipsin is an adipokine that improves β cell function in diabetes. Cell 158, 41-53 (2014).
30. Ahrén, B., Havel, P. J., Pacini, G. & Cianflone, K. Acylation stimulating protein stimulates insulin secretion. Int. J. Obes. Relat. Metab. Disord. 27, 1037-43 (2003).
31. Ahrens, K. et al. Serum leptin levels and reproductive function during the menstrual cycle. Am. J. Obstet. Gynecol. 210, 248.e1-9 (2014).
32. Fattah, C. et al. Maternal leptin and body composition in the first trimester of pregnancy. Gynecol. Endocrinol. 27, 263-266 (2011).
33. Van der Wijden, C. L., Delemarre-van der Waal, H. A., van Mechelen, W. & van Poppel, M. N. M. The concurrent validity between leptin, BMI and skin folds during pregnancy and the year after. Nutr. Diabetes 3, e86 (2013).
34. Salimi, S. et al. Different Profile of Serum Leptin between Early Onset and Late Onset Preeclampsia. Dis. Markers 2014, 1-7 (2014).
35. Mendieta Zerón, H. et al. Hyperleptinemia as a prognostic factor for preeclampsia: A cohort study. Acta Medica (Hradec Kralove) 55, 165-171 (2012).
36. Papastefanou, I. et al. Correlation between maternal first trimester plasma leptin levels and birth weight among normotensive and preeclamptic women. J. Matern. Neonatal Med. 23, 1435-1443 (2010).
37. Saleh, J., Al-Riyami, H. D. S., Chaudhary, T. A. & Cianflone, K. Cord blood ASP is predicted by maternal lipids and correlates with fetal birth weight. Obesity (Silver Spring). 16, 1193-8 (2008).
38. Sivakumar, K. et al. Elevated fetal adipsin/acylation-stimulating protein (ASP) in obese pregnancy: novel placental secretion via Hofbauer cells. J. Clin. Endocrinol. Metab. 98, 4113-22 (2013).
39. Maslowska, M. et al. Plasma acylation stimulating protein, adipsin and lipids in non-obese and obese populations. Eur. J. Clin. Invest. 29, 679-86 (1999).
40. Zhu, L. et al. The endogenous vascular elastase that governs development and progression of monocrotaline-induced pulmonary hypertension in rats is a novel enzyme related to the serine proteinase adipsin. J. Clin. Invest. 94, 1163-71 (1994).
41. Sodowski, K. et al. Acylation stimulating protein is associated with pregnancy weight gain. J. Physiol. Pharmacol. 59 Suppl 4, 33-43 (2008).
42. Murray, I., Sniderman, A. D. & Cianflone, K. Enhanced triglyceride clearance with intraperitoneal human acylation stimulating protein in C57BL/6 mice. Am. J. Physiol. 277, E474-80 (1999).
43. Van den Hoek, A. M. et al. Chronic PYY3-36 treatment promotes fat oxidation and ameliorates insulin resistance in C57BL6 mice. Am. J. Physiol. Endocrinol. Metab. 292, E238-45 (2007).
44. Saleh, J. et al. Increased plasma acylation-stimulating protein correlates with hyperlipidemia at late gestation. Obesity (Silver Spring). 15, 646-52 (2007).
45. Koçyigit, Y., Atamer, Y., Atamer, A., Tuzcu, A. & Akkus, Z. Changes in serum levels of leptin, cytokines and lipoprotein in preeclamptic and normotensive pregnant women. Gynecol. Endocrinol. 19, 267-73 (2004).
46. Dani, C. et al. Regulation of gene expression by insulin in adipose cells: opposite effects on adipsin and glycerophosphate dehydrogenase genes. Mol. Cell. Endocrinol. 63, 199-208 (1989).
47. Lowell, B. B. & Flier, J. S. Differentiation dependent biphasic regulation of adipsin gene expression by insulin and insulin-like growth factor-1 in 3T3-F442A adipocytes. Endocrinology 127, 2898-906 (1990).
48. Miner, J. L., Byatt, J. C., Baile, C. A. & Krivi, G. G. Adipsin expression and growth in rats as influenced by insulin and somatotropin. Physiol. Behav. 54, 207-12 (1993).
49. Brelje, T. C. et al. Effect of homologous placental lactogens, prolactins, and growth hormones on islet B-cell division and insulin secretion in rat, mouse, and human islets: implication for placental lactogen regulation of islet function during pregnancy. Endocrinology 132, 879-87 (1993).
50. Luo, Z.-C. et al. Maternal and fetal leptin, adiponectin levels and associations with fetal insulin sensitivity. Obesity (Silver Spring). 21, 210-6 (2013).
51. Wolf, H. J. et al. Fetal leptin and insulin levels only correlate inlarge-for-gestational age infants. Eur. J. Endocrinol. 142, 623-9 (2000).
52. Grattan, D. R., Ladyman, S. R. & Augustine, R. A. Hormonal induction of leptin resistance during pregnancy. Physiol. Behav. 91, 366-74 (2007).
53. Augustine, R. A. & Grattan, D. R. Induction of central leptin resistance in hyperphagic pseudopregnant rats by chronic prolactin infusion. Endocrinology 149, 1049-55 (2008).
54. Catalano, P. M. et al. Adiponectin in human pregnancy: implications for regulation of glucose and lipid metabolism. Diabetologia 49, 1677-85 (2006).
55. Mazaki-Tovi, S. et al. Maternal serum adiponectin levels during human pregnancy. J. Perinatol. 27, 77-81 (2007).
56. Ahlsson, F. et al. Adipokines and their relation to maternal energy substrate production, insulin resistance and fetal size. Eur. J. Obstet. Gynecol. Reprod. Biol. 168, 26-9 (2013).
57. Lu, H. et al. Inflammatory markers and adipokines alter adipocyte-derived ASP production through direct and indirect immune interaction. Exp. Clin. Endocrinol. Diabetes 121, 194-200 (2013).
58. Hoffman, M. C., Rumer, K. K., Kramer, A., Lynch, A. M. & Winn, V. D. Maternal and fetal alternative complement pathway activation in early severe preeclampsia. Am. J. Reprod. Immunol. 71, 55-60 (2014).
59. Velickovic, I. et al. Complement factor B activation in patients with preeclampsia. J. Reprod. Immunol. 109, 94-100 (2015).
60. Takeshita, A., Kondo, T., Okada, T. & Kusakabe, K. T. Elevation of adipsin, a complement activating factor, in the mouse placenta during spontaneous abortion. J. Reprod. Dev. 56, 508-14 (2010).
61. Wirstlein, P., Mikolajczyk, M. & Skrzypczak, J. Assessment of the transcription levels for the complement activation control system in eutopic endometrium in women with two or more consecutive miscarriages of unknown etiology. Folia Histochem. Cytobiol. 48, 328-332 (2010).
62. Takeshita, A. et al. Dynamics and reproductive effects of complement factors in the spontaneous abortion model of CBA/J DBA/2 mice. Immunobiology 219, 385-91 (2014).
63. Quinton, N. D. et al. Serum leptin levels during the menstrual cycle of healthy fertile women. Br. J. Biomed. Sci. 56, 16-19 (1999).
64. Garcés, M. F. et al. Longitudinal analysis of maternal serum Follistatin concentration in normal pregnancy and preeclampsia. Clin. Endocrinol. (Oxf). (2015). doi: 10.1111/cen.12715
65. Hypertension in pregnancy. Report of the American College of Obstetricians and Gynecologists' Task Force on Hypertension in Pregnancy. Obstet. Gynecol. 122, 1122-31 (2013).
66. Matthews, D. R. et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28, 412-9 (1985).